The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20141601: Gryphon Partners 3.5, L.P.; Orchid Underwriters Agency, Inc.
20141602: Global Cash Access Holdings, Inc.; Multimedia Games Holding Company, Inc.
20141603: EnerVest Energy Institutional Fund XIII-C, L.P.; Loews Corporation
20141604: Roger S. Penske; ATC Holdco, LLC
20141496: Pershing Square Holdings, Ltd.; Canadian Pacific Railway Limited
20141572: Alliance Data Systems Corporation; Conversant, Inc.
Pinnacle Payment Services, LLC
20141506: Behrman Capital IV, L.P.; Nautic Partners VI, L.P.
20141512: Court Square Capital Partners III, L.P.; Pike Corporation
20141561: Intercontinental Exchange, Inc.; Super Derivatives, Inc.
Federal Trade Commission Comment Before the Federal Communications Commission Regarding the Privacy and Security Practices of Broadband Providers and Their Impact On Broadband Adoption
20141472: JLL Patheon Co-Investment Fund, L.P. (Cayman); Gallus BioPharmaceuticals, LLC
20141519: 1-800-FLOWERS.COM, Inc.; Harry & David Holdings, Inc.
Akorn, Inc., In the Matter of
Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive. According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin and there are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin – which is currently pending before the Food and Drug Administration – to Watson Laboratories, Inc.